Jupiter Neurosciences (NASDAQ:JUNS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Jupiter Neurosciences (NASDAQ:JUNS) from a strong sell rating to a sell rating in a research report report published on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Jupiter Neurosciences presently has a consensus rating of “Sell”.

Jupiter Neurosciences Stock Performance

Jupiter Neurosciences stock opened at $5.24 on Friday. The firm has a market capitalization of $4.03 million, a price-to-earnings ratio of -0.27 and a beta of 1.99. Jupiter Neurosciences has a fifty-two week low of $4.56 and a fifty-two week high of $137.96. The stock’s fifty day moving average is $12.93 and its two-hundred day moving average is $25.12.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings results on Friday, August 14th. The company reported ($5.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($5.01). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.40 million.

Institutional Investors Weigh In On Jupiter Neurosciences

Large investors have recently bought and sold shares of the stock. Allen Capital Group LLC acquired a new stake in Jupiter Neurosciences during the fourth quarter worth about $31,000. Geode Capital Management LLC grew its holdings in shares of Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Yorkville Advisors Global LP acquired a new stake in Jupiter Neurosciences during the 4th quarter worth approximately $135,000. Finally, Vestor Capital LLC increased its position in Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares in the last quarter.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.